Eli Lilly: research collaboration with Totus Medicines
Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to generate high-quality covalent compounds against Eli Lilly's targets.
Thereafter, Lilly and Totus will have the option to exclusively pursue preclinical and clinical development and commercialization of the compounds identified during the collaboration, and to receive milestone payments.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction